BSE filing, NSE: VIKASWSP. Summary written from the filing by ALFA Finder's alert engine.
Vikas WSP Ltd: key numbers
- Share price
- ₹0.84
- Market cap
- ₹17.17 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-66.98 Cr
- P/E (TTM)
- -0.3×Sector 51.9×
- Promoter holding
- 14.56%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vikas WSP Ltd
All →Vikas WSP Board Meeting Date
Vikas WSP will hold a board meeting on 12 November 2026 to consider unaudited standalone September 2026 quarter results. Trading window stays closed until 14 November 2026.
Vikas WSP Insolvency Petition
Vikas WSP Ltd's CIRP Resolution Plan was approved by NCLT Chandigarh on September 9, 2026. The company continues under the Interim Resolution Professional per IBC 2016.
Vikas WSP Other Announcement
Vikas WSP Ltd has applied to the Registrar of Companies for a three-month extension to hold its Annual General Meeting for the financial year 2025-26.
Vikas WSP Other Announcement
The company filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with Regulation 31(1)(b) of SEBI LODR.
Vikas WSP Q1 FY27 Results: Net Loss of ₹0.3 Cr, Loss Narrows
Vikas WSP Ltd reported a net loss of ₹0.3 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.3 Cr
Vikas WSP Board Meeting Date
Vikas WSP Limited has scheduled a board meeting on August 14, 2026, to approve quarterly financial results. The board will also consider auditor re-appointment and an AGM extension.
Other other announcement announcements
All →Kansai Nerolac Paints Other Announcement
Kansai Nerolac authorised Pravin Chaudhari, Yash Ahuja and Rukmini Subramanian to determine material events from 1 December 2026. It only lists KMP and contact details.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.